Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 33 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/12/2008


1.		Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-1694 CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9

Last Modified: 12/8/2008 First Published: 1/1/1999


2.		Phase III Multicenter, Randomized, Controlled Study of THERATOPE Vaccine in Women With Metastatic Breast Cancer (Summary Last Modified 05/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				BIOMIRA-STn-BR-104 NCI-V98-1489, NCT00003638

Last Modified: 6/11/2008 First Published: 7/1/2000


3.		Phase III Randomized Study of BCI-ImmuneActivator™ (Keyhole Limpet Hemocyanin) Versus Doxorubicin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Temporarily closed				18 and over				Pharmaceutical / Industry				INTRACEL-BCI-9804-04 NCT00006034

Last Modified: 12/27/2008 First Published: 6/1/2001


4.		Phase III Randomized Study of Cyclophosphamide, Prednisone, and Vincristine Followed By Immunotherapy With Keyhole Limpet Hemocyanin With or Without Recombinant Autologous Tumor-Derived Immunoglobulin Idiotype and Adjuvant Sargramostim (GM-CSF) in Patients With Stage III or IV Follicular B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GENITOPE-G2000-03 CUMC-0101-142, UCLA-0010061, NCT00017290

Last Modified: 3/1/1995


5.		Phase I/II Pilot Study of Anti-Idiotypic MOAB BEC2 Conjugated to KLH plus BCG as Adjuvant in Completely Resected Melanoma (Summary Last Modified 03/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				MSKCC-94078 NCI-H94-0538

Last Modified: 12/27/2008 First Published: 10/1/2000


6.		Phase I/II Study of Purified Myeloma Protein Immunization in Sibling Peripheral Blood Stem Cell (PBSC) Donors and in Patients With Multiple Myeloma Who Are Undergoing Nonmyeloablative Chemotherapy and HLA-Matched Allogeneic PBSC Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to 75				NCI				NCI-00-C-0201 NCI-1029, 1029, NCT00020306

Last Modified: 12/23/2008


7.		Phase II Study of Tumor-Derived Immunoglobulin Idiotype Vaccination and Sargramostim following Cyclophosphamide/Doxorubicin/Etoposide/Prednisone in Low-Grade Follicular Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-96-C-0133 CRB-9309, NCI-T93-0164N, T93-0164

Last Modified: 5/1/1998


8.		Phase II Randomized, Double-Blind Study of 3 Doses of Sialyl Tn-KLH Therapeutic Vaccine with Detox B Adjuvant as Active-Specific Immunotherapy for Colorectal Cancer (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 75				Other				UNMC-04094 NCI-V94-0589

Last Modified: 12/23/2008


9.		Phase II Study of Active Immunization of Related Bone Marrow Transplant Donors Against Purified Myeloma Protein from the Recipient Undergoing Allogeneic Bone Marrow Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				under 60				NCI				NCI-97-C-0030B CRB-9407, NCI-T94-0085N, T94-0085

Last Modified: 12/23/2008


10.		Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-97-C-0033B CRB-9409, NCI-T94-0094N, T94-0094, NCT00019097

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute